MedTrace Logo

To Evaluate Safety and Efficacy of EC-18 in COVID-19 Infection to Pneumonia

NCT04500132 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 63

Last updated 2022-02-10

No results posted yet for this study

Summary

Prevention of COVID-19 infection to severe pneumonea or ARDS

Conditions

Interventions

DRUG

EC-18

EC-18 QD

DRUG

Placebo EC-18

Placebo EC-18 QD

Sponsors & Collaborators

  • Enzychem Lifesciences Corporation

    lead INDUSTRY

Principal Investigators

  • Hyewon Jeong · Chungbuk National University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-05-28
Primary Completion
2021-02-04
Completion
2021-02-15

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04500132 on ClinicalTrials.gov